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5Introductory note and acknowledgements
In-depth reviews of topical interest are published as Selected issues each year. These reports are based on information 
provided to the EMCDDA by the EU Member States, the candidate countries Croatia and Turkey, and Norway as part of the 
national reporting process.
The most recent Selected issues are:
•  Guidelines for the treatment of drug dependence: a European perspective;
•  Cost and financing of drug treatment services in Europe: an exploratory study;
•  Treatment and care for older drug users;
•  Problem amphetamine and methamphetamine use in Europe;
•  Trends in injecting drug use in Europe;
All Selected issues (in English) and summaries (in up to 23 languages) are available on the EMCDDA website:  
http://www.emcdda.europa.eu/publications/selected-issues
The EMCDDA would like to thank the following for their help in producing this Selected issue:
•  the heads of Reitox national focal points, their staff and the national experts on drug-related deaths;
•  the services within each Member State that collected the raw data;
•  the members of the Management Board and the Scientific Committee of the EMCDDA;
•  the Publications Office of the European Union.
Reitox national focal points
Reitox is the European information network on drugs and drug addiction. The network is comprised of national focal points in the EU 
Member States, Norway, the candidate countries and at the European Commission. Under the responsibility of their governments, 
the focal points are the national authorities providing drug information to the EMCDDA.
The contact details of the national focal points may be found at: 
http://www.emcdda.europa.eu/about/partners/reitox-network

7Introduction
In recent decades, the overall level of illicit drug use in 
Europe has risen dramatically, and with it the number of 
deaths among the drug-using population, in particular 
among problem drug users. In the 21st century, a 
considerable share of premature or avoidable mortality 
among young adults can be attributed to illicit drug 
overdose, which accounts for an estimated 4% of deaths 
among those aged 15–39 in Europe (1). These deaths are 
often related to injecting drug use and, in most cases, involve 
a combination of substances (Best et al., 2000), but they 
represent only part of mortality among drug users (2). In 
addition, a substantial number of deaths are indirectly 
related to drug use, such as those from HIV/AIDS related to 
injecting drug use, accidents, violence and suicides. The high 
levels of mortality among drug users are a serious cause for 
concern both at the individual and the societal level.
The number of problem opioid users in Europe is cautiously 
estimated at about 1.3 million (3), and it is among these 
opioid users, particularly injectors, that we find the greatest 
share of morbidity and mortality related to illicit drug use in 
Europe. Heroin is the drug most often associated with 
overdose, although other drugs and alcohol are commonly 
present. Overdose represents a major cause of avoidable 
death associated with illicit drug use, and from 1990 to 
2010, between 6 500 and 8 500 overdose deaths have 
(1) See Table DRD-5 in the 2011 statistical bulletin.
(2) We focus on illicit drug use, in particular the more harmful forms of use and exclude alcohol, tobacco and medicine alone.
(3) See glossary for a definition of problem drug use and Table PDU-1 in the 2011 statistical bulletin for available national estimates.
Mortality related to drug use: a complex 
phenomenon 
Drug use can cause death directly by toxicity, either acute (e.g. 
overdoses) or chronic (e.g. cirrhoses or cardiovascular 
diseases), or by a variety of indirect effects including: 
facilitating the transmission of infectious diseases by certain 
patterns of use (e.g. sharing injection equipment); by 
circumstances surrounding drug dealing and social context 
(e.g. crime, violence); or by affecting the mental state (e.g. 
suicide) or psychomotor responses of the user (e.g. traffic 
accidents). In many cases of drug-related death, with the 
obvious exception of overdoses, drug use has contributed to but 
not caused the death by itself. Sometimes, it is difficult to assess 
if the death of a drug user, for example someone dying in a 
traffic accident, can be attributed to drug use. Furthermore, 
drugs are often found in post-mortem toxicology, although they 
may not have contributed to the death (Corkery, 2008). 
In order to monitor some of the major components of drug-
related mortality, the EMCDDA has defined an epidemiological 
indicator: ‘Drug-induced deaths and mortality among drug 
users’. The indicator has two complementary components: 
deaths caused directly by and within a short time of the 
consumption of illicit drugs (commonly known as overdoses and 
referred to here as drug-induced deaths), and mortality among 
problem drug users. 
The first and core component of the EMCDDA indicator is 
based on national statistics on drug-induced deaths, which are 
collected each year by almost all European countries. The 
second component, mortality among problem drug users is 
mainly based on longitudinal cohort studies. This component 
incorporates both overall mortality and cause-specific mortality 
(EMCDDA, 2011b). The number and type of overdose deaths 
can be seen as a reflection of the current patterns of drug use 
in society. Overall mortality, in contrast, can be influenced by 
other concurrent factors, such as the prevalence of HIV 
infection, violence related to drug dealing, and access to drug 
treatment. Together, these two components aim to fulfil a 
number of public health objectives: they can give an indication 
on the overall health impact of drug use and the different 
factors involved, and they can help to identify particularly risky 
patterns of use and potential new risk factors.
Mortality related to drug use in Europe: public health implications
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been reported each year in Europe. Somewhat surprisingly, 
however, given major increases in provision of drug 
treatment and effective HIV/AIDS treatment in Europe, the 
number of overdose deaths has been on the increase in most 
EU Member States in recent years. 
But beyond overdoses, mortality related to drug use is a 
complex phenomenon, with a number of dimensions that 
require different data sources and methodology to help 
explain them (4). 
This Selected issue focuses on mortality among drug users 
due to all causes, of which drug-induced deaths is only a 
component, albeit the one most well-documented. The 
publication begins with an introduction to mortality cohort 
studies and then reviews the findings on overall mortality 
rates in Europe. In the following sections, the available 
sources of data are examined to explore the main causes of 
deaths among drug users, including overdose, suicide, 
trauma and infectious diseases, as well as the latest 
information on risk and protective factors. The Selected issue 
finishes with a discussion of the public health implications of 
drug-related mortality and the options available for 
prevention and intervention.
Data sources
This Selected issue is based on a special data collection 
carried out in 14 European countries (Figure 1), 
supplemented by data routinely collected by the EMCDDA 
and results from the scientific literature. 
Mortality cohort studies among drug users in Europe 
published since the mid-1990s provide a major source of 
data for this publication. The main European mortality 
studies that have been analysed here are presented in the 
Appendix. The studies have been selected primarily to cover 
as many countries as possible, and according to the size of 
the population followed up. Recent long-term follow-up 
studies conducted at national level and enrolling between 
3 000 and 5 000 participants are available for Germany, 
Latvia, Poland, Slovenia, Sweden, Croatia and Norway. 
Studies conducted in other settings, such as juvenile 
correctional institutions, are available for some countries. 
While many of these studies have been published, some 
countries have provided cohort data that are as yet 
unpublished. The participants in the cohort studies analysed 
here are predominantly problem drug users, most of whom 
were engaged in opioid substitution treatment or some other 
form of treatment for opioid dependence at the time of their 
enrolment.
Figure 1: Countries participating in the special data collection for 
this Selected issue (yellow) and countries participating in the 2010 
workshop on mortality data analysis or the EMCDDA mortality 
cohort COSMO group (blue star)
In addition to mortality cohorts, other follow-up studies, with 
different primary objectives or recruitment criteria can also 
be used to monitor mortality. Examples include the VEdeTTE 
Study in Italy (Bargagli et al., 2006a; Davoli et al., 2007; 
Ferri et al., 2007; Vigna-Taglianti et al., 2007), the primary 
objective of which was to assess treatment outcome, studies 
among those arrested for drug law offences in France 
(Lopez et al., 2004), and studies of injectors with hepatitis in 
the Czech Republic (Lejckova and Mravcik, 2005, 2007). 
Statistics on drug-induced deaths in Europe, derived from 
general mortality registries or special registries, usually 
medico-legal databases (EMCDDA, 2010b), have also been 
analysed in this Selected issue.
Finally, data from epidemiological surveillance of the 
general population are also used to identify trends in deaths 
related to HIV/AIDS among injecting drug users.
What are cohort studies and what do they tell us?
The information analysed in this Selected issue is mainly 
derived from longitudinal follow-up studies of groups — 
‘cohorts’ — of problem drug users, which systematically 
identify the causes of all deaths among the cohort. 
Cohort studies may be classified by whether they use an 
active or passive follow-up. Active follow-up studies allow 
researchers to measure behaviour over time, for example the 
(4) See the box ‘Mortality related to drugs: a complex phenomenon’.
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duration of treatment over the years, or whether the person 
has changed his primary drug. Passive follow-up methods 
link records between lists of drug users and mortality 
registries, but cannot collect information on the subsequent 
drug-use or drug-treatment history of the participant after 
enrolment in the study. 
Mortality cohort studies among problem drug users can 
determine overall and cause-specific mortality rates and 
can estimate the excess mortality of drug users, 
compared to their peers in the general population. 
Large-scale cohort studies can also help to determine the 
impact of interventions. For example, cohort studies 
provide insight into the trends of HIV/AIDS-related 
mortality among injecting drug users, which decreased 
dramatically after the introduction of effective HIV 
treatment. Cohort studies monitor the overall mortality 
risk and detect changing patterns in the causes of death 
(Darke et al., 2007a). 
Findings from cohort studies can be used to produce 
national estimates of deaths among problem drug users. For 
that, mortality rates can be extrapolated from cohort studies 
to local or national estimates of the number of problem drug 
users (Cruts et al., 2008). Another approach that can be 
used to estimate the number of deaths due to drug use is to 
derive drug-attributable fractions from mortality cohort 
studies and apply these fractions to the causes of death that 
are most frequently related to drug use (e.g. HIV/AIDS, 
accidents, suicide and poisonings) and which are recorded 
in the general population mortality registries. Findings from 
cohort studies can also contribute to the validation of data 
from other sources, for example, the number of reported 
drug-induced deaths. 
Cohort studies have both strengths and limitations when 
used for the study of mortality among drug users. The 
capacity to provide information on mortality from all causes 
among drug users, beyond drug-induced deaths, is the main 
advantage of mortality cohort studies. Their main limitation 
is that they underestimate the number of deaths when some 
subjects are lost to follow-up. In addition, the results may not 
be readily generalised to other populations of drug users. 
Finally, comparability between studies can be compromised 
by differences in recruitment settings (e.g. treatment centres, 
outreach services, needle exchange services), populations of 
drug users enrolled (e.g. cocaine users, arrestees) and study 
design (e.g. enrolment of current drug users, retrospective 
studies of persons treated some years ago) (Degenhardt et 
al., 2011a).
Comparable mortality cohort studies:  
EMCDDA protocol
A protocol on conducting mortality cohort studies has been 
produced by the EMCDDA and national experts to assist 
European countries in carrying out useful and comparable 
studies (EMCDDA, 2011b). The EMCDDA protocol 
recommends the use of treatment centres as the setting for 
recruitment of patients into cohort studies. 
Treatment centres are usually able to recruit a relatively 
representative sample of problem drug users in treatment, 
typically, opioid users. They are also an appropriate setting 
for the collection of personal identifiers needed to trace the 
participants in mortality registries. There are, however, 
limitations associated with recruiting drug users in these 
settings, as the findings are not necessarily transposable to 
other drug users, particularly those not in treatment. 
To facilitate comparison across studies, the EMCDDA also 
recommends the use of prospective studies that focus on 
current drug users: participants are enrolled on entry to 
drug treatment and the study looks at mortality over the 
following months or years. Some studies are retrospective, 
that is to say the individuals have been enrolled in the 
past, at the moment of intake to treatment. However, in 
these studies, there might be gaps, errors, and non-
standard data, which will be difficult or impossible to 
complete or correct. 
The EMCDDA stresses the necessity of confidentiality and 
protection of identifiable personal data. Ethical approval 
and participants’ consent are needed, as is compliance 
with national regulations and laws.
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Several tens of thousands of problem drug users have been 
enrolled in cohort studies over the last 20 years in Europe, 
and thousands of deaths have been recorded. 
High mortality rates among problem drug 
users
Depending on recruitment setting (Degenhardt et al., 2011a) 
and enrolment criteria, most cohort studies carried out show 
mortality rates in the range of 1–2% per year among 
problem drug users (or 10–20 per 1 000 person-years) (see 
some examples in the Appendix). This rate appears to have 
been relatively stable over the last decade. Most of the 
participants in these studies are males (around 8 in 10), who 
at the time of enrolment were aged 15 to 34 years and were 
using opioids problematically. 
How many Europeans may die every year because 
of problem opioid use? 
Although it is difficult to obtain a precise figure, findings from 
cohort studies, in combination with figures on overdoses and 
estimates of the total number of opioid users in Europe, can be 
used in a number of ways to make crude estimates of the overall 
number of European deaths related to problem opioid use (1).
A first approach is based on the assumption, using the results of 
many mortality cohort studies, that overdose deaths account for 
between one-third and half of all deaths among problem drug 
users (see examples in Table 1). The estimated 7 600 overdose 
deaths in Europe for 2009 would therefore suggest an overall 
mortality of roughly between 15 200 (twice the number of 
overdoses) and 22 800 (three times the number of overdoses) 
(see estimation 1 below).
A second approach applies the range of mortality rates of 
opioid users observed in most cohort studies (between 1% and 
2% per year) to the estimated number of problem opioid users in 
Europe (1 300 000) (2) to obtain a central estimate or range of 
between 13 000 and 26 000 deaths each year. See estimation 
2a below. The estimate could be roughly refined by noting that 
opioid substitution treatment is expected to reduce the mortality 
rate during treatment by approximately two-thirds (Bargagli et 
al., 2007), and that the number of individuals reported to the 
EMCDDA as receiving opioid substitution treatment in a year is 
about half the estimated number of problem opioid users (3). 
Incorporating these figures into the calculation (mortality rates of 
between 0.33% — one third of 1% — and 0.66% — one third of 
2% — applied to half the estimated number of problem opioid 
users) modifies the estimate to between 8 700 and 17 300 
deaths (see estimation 2b below).
All estimations require caution, as they rely on the one hand on 
broad estimates of the proportion of overdoses to all deaths 
among opioid users, and on the other in combining estimates of 
mortality rates and the total number of opioid users in Europe. 
Nevertheless, there is some agreement between the results, and 
given the information that is available at present, these figures 
suggest a credible range for the number of deaths in Europe 
due to problem opioid use. Bearing in mind the data limitations 
and caveats mentioned above, it can be roughly estimated that 
somewhere between 10 000 and 20 000 problem opioid 
users die every year in Europe.
(1) For more details on the computations and assumptions and limitations please see Drug-related deaths on the EMCDDA website.
(2) See Table PDU-1 in the 2011 statistical bulletin.
(3) See Table HSR-3 in the 2011 statistical bulletin 2011.
25 00020 00015 00010 0005 0000
15 200 22 800
Estimation 1:
all POU deaths:
Estimation 2a: 
all POU deaths
Estimation 2b: all POU deaths
(corrected for effect of treatment)
13 000 26 000
8 700
 
17 300
7 600
Overdoses 
Deaths per year 
Estimates of overall mortality related to problem opioid use
NB: POU, problem opioid users.
Key findings from recent mortality cohorts in Europe
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Compared to the general population, both male and female 
opioid users have very high mortality rates (5), and most of 
these studies show slightly higher rates of mortality among 
male than female participants. A recent international review 
found that the crude mortality rates for males were 1.3 times 
those of females. Looking at drug-induced deaths, the 
difference between genders was larger, with the rates of 
crude mortality due to drug overdose among males being 1.7 
times higher than those of females (Degenhardt et al., 2011a).
Excess risk of death among problem drug 
users
Mortality cohort studies point to an excess risk of mortality 
for problem drug users compared with their peers of the 
same age and gender in the general population. Overall, 
the mortality for drug users is roughly 10 to 20 times that of 
the general population of the same age and gender (6). 
Comparison between studies needs to be undertaken with 
caution, however, as the values depend on the baseline 
levels of mortality, which differ across countries.
Although female problem drug users have similar or lower 
mortality rates than males, their excess risk of death is 
higher than that of their male counterparts, as illustrated in a 
recent study among opioid users in Latvia (Figure 2). This is 
primarily due to lower mortality rates among women than 
men in the general population, which in turn is largely due 
to fewer women dying from violent causes. Elevated excess 
risk in female drug users was illustrated by the COSMO 
study carried out in eight European cities (Bargagli et al., 
2006b). Although overall mortality rates were consistently 
slightly higher among males, the excess risk for females was 
considerably higher than that for males. In Barcelona, the 
risk of death among drug-using women was 54 times that of 
women in the general population, whereas drug-using men 
had a risk 21 times that of men in the general population. In 
Rome, the respective figures were 38 for female drug users 
and 14 for male drug users (Bargagli et al., 2006b; Bird, 
2010). The high mortality rates among drug users observed 
at that time (all studies started between 1990 and 1996) 
were due in part to the high HIV/AIDS mortality. 
Excess mortality risk is usually higher in younger drug users 
than in older ones, again largely due to lower mortality 
rates among their peers in the general population. In a 2010 
Romanian study, for example, the youngest group of 
drug-users enrolled (aged 15–19 years) had a 20-times 
higher risk of death compared with their same-aged peers, 
whereas the overall excess mortality rate for the whole study 
population was six. 
From a public health perspective, information on the levels 
of excess risk of death associated with drug-using behaviour 
can be a useful tool for epidemiologists and policymakers as 
they design and target interventions. 
A number of European studies have estimated the excess risk 
of death associated with specific causes. For example, a 
study in France among people arrested for heroin, cocaine 
or crack use showed that the participants had considerably 
higher risks of mortality due to AIDS compared with the 
general population (24 times higher for males and 29 times 
higher for females), accidents (4 and 10 times higher) and 
suicide (3 and 13 times higher). In addition, male drug users 
in the study were 11 times more likely to die of homicide than 
their peers in the general population (Lopez et al., 2004).
Survival analysis provides an insight into the years of life 
lost, as the risk of death accumulates over time. After 10 
years, with mortality rates of 1–2% per year, up to 20% of 
the drug users enrolled in a study can be dead. For 
example, a group of three studies conducted in Latvia with 
follow-up until 2010 recorded the deaths of 575 individuals. 
Overall, 1% to 2% of the participants died in the first year of 
the studies, by the end of the studies’ fifth year between 4% 
and 7% had died, and between 15% and 18% of 
participants had died after 10 years. 
(5) See ‘Excess risk of death among problem drug users’.
(6) See mortality ratios in the Appendix.
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Figure 2: Mortality rates in opioid users and excess mortality risk 
compared to the general population, by gender: a Latvian cohort study
NB:  Mortality rates in cohort participants (opioid users) compared to those 
in the general population, and the ratio between the two 
(standardised mortality ratios) for males and females aged 15–49. 
Follow-up period: 2000–09. Number of subjects followed up: 3 644.
Source: Trapencieris, 2010 (unpublished).
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What are the major causes of death among problem drug users?
Four broad categories of causes of deaths among drug 
users have been identified, including overdoses, disease, 
suicide and trauma (Darke et al., 2007a), and the 
following section of the report is structured around these. 
Among diseases, conditions related to blood-borne 
viruses (HIV, hepatitis B and hepatitis C viruses), 
neoplasms, liver diseases, and diseases of the respiratory 
and circulatory systems can be associated with drug use. 
Trauma refers to serious or critical wounds or bodily 
injuries such as from accidents (traffic accidents, falls, 
drowning) and violence, and includes assault and 
homicide. 
Among problem drug users, in particular, cause of death 
may not be clear-cut. Those with severe drug problems, 
especially opioid users, comprise a very vulnerable 
population. Often, they have additional problems such as 
psychiatric co-morbidity, social exclusion, difficulties to 
Table 1: Causes of deaths in selected recent cohort studies among problem drug users in Europe
Country and reference Total 
number of 
deaths 
Ill defined, 
unknown, 
unspecified (%)
Overdose 
(%)
HIV/AIDS 
(%)
Suicide (%) Trauma, 
accident (%)
Others (%)
Germany (Soyka et al., 2006) 28 3.6 39.3 10.7 10.7 10.7 25.0
Italy (Ferri et al., 2007) 190 11.1 36.8 20.0 1.6 14.2 16.3
Latvia (Trapencieris, 2010, 
unpublished)
269 1.1 14.9 10.8 11.9 13.0 48.3
Malta (Calleja, 2010, 
unpublished)
55 0.0 47.3 1.8 10.9 21.8 18.2
Romania (Botescu et al., 2010, 
unpublished)
116 4.3 33.6 3.4 13.8 7.8 37.1
Slovenia (Selb, 2010, unpublished) 69 0.0 36.2 0.0 24.6 21.7 17.5
United (Bloor et al., 2008) 38 2.6 57.9 7.9 15.8 7.9 7.9
United Kingdom (Farrell and 
Marsden, 2008) (1)
442 0.0 57.0 0.0 8.1 22.6 12.2
United Kingdom, England 
(Hickman et al., 2003)
33 12.1 63.6 0.0 0.0 6.1 18.2
United Kingdom, Scotland (Kimber 
et al., 2010) (2)
112 0.9 38.4 38.4 7.1 0.0 15.2
United Kingdom, Scotland 
(McCowan et al., 2009)
181 8.3 33.1 7.7 7.2 (3) 43.6
Norway (Clausen et al., 2009) 213 2.3 53.1 8.0 4.7 8.9 23.0
Croatia (Pejak, 2010, unpublished) 174 12.6 54.0 0.6 0.0 8.0 24.7
(1) Newly released prisoners. 
(2) Long-term follow-up with enrolment from 1980 to 2006. Localised HIV epidemic. Deaths before long-term cessation.
(3) Includes suicide.
NB:  The studies presented here have been selected for the completeness of the information provided on causes of deaths, and are not intended to be 
representative of the population of problem drug users in Europe. As most studies are from low-HIV prevalence countries, the impact of HIV is probably far 
less than in other countries such as Spain, Italy and Portugal. Comparison of the studies should be made with caution as they differ in settings and 
enrolment criteria. More information, including study period, population, recruitment setting and mortality rates is available in the Appendix.
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access services, alcohol use and dependence, which can 
cause considerable harm in their own right. 
Results from a selection of studies presented in Table 1, 
which are also supported by results from other reports, show 
that while there can be great variation between studies, a 
rough generalisation can be made that between one-third 
and half of deaths among drug users are due to overdose, 
while between one-fifth and two-fifths are due to suicide and 
trauma. Less than a tenth is reportedly due to HIV/AIDS. A 
substantial proportion of drug users die from other causes, 
which in the studies cited here typically account for about a 
quarter of all deaths, though this category can represent up 
to half of recorded deaths in some cohorts. The category 
‘other causes’ appears to include mostly somatic and chronic 
conditions, such as liver disease, cardiovascular and 
pulmonary causes, cancer, and other infections. Deaths from 
unknown causes are rare in this selection of studies, but they 
can account for a high number of deaths in some mortality 
studies. In general, comparison between studies needs to be 
made with caution, as the studies’ populations and settings 
vary, as do the coding procedures of causes of deaths.
Overdoses
Opioids, particularly heroin, are by far the drugs most 
often implicated in overdoses (7), with fatalities primarily 
linked to respiratory depression. In Europe, there are 
around 7 500 cases reported every year, and numbers 
have been stable or increasing for the last five years in 
most reporting countries (EMCDDA, 2011a; Vicente et al., 
2009).
In a multi-site EMCDDA study conducted in eight European 
countries, overdoses accounted for between 28% and 60% 
of the reported deaths among participants (Figure 3). An 
exception to this finding was Portugal, where overdoses 
accounted for 7% of the deaths among drug users; this was 
due to the high proportions of deaths either caused by HIV/
AIDS, or ill-defined, of which some were likely to be 
overdoses (Bargagli et al., 2006b). Results from recent 
mortality cohort studies in Europe suggest that drug-induced 
deaths often represent between a third and a half of the 
overall number of fatalities among problem drug users (see 
examples in Table 1). 
(7) See the box ‘Mortality among cocaine and amphetamine users’.
Figure 3: Causes of deaths in the EMCDDA COSMO studies, and in more recent selected studies in Europe
Sources: Bargagli et al. (2006b) and Reitox national focal points.
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Those dying of drug overdose are predominantly in their early 
to mid-thirties, and have a long history of drug use. In recent 
years, the mean age of drug-induced deaths reported in 
Europe has been increasing, pointing to an ageing population 
of problem opioid users in many EU Member States (8). 
Gender appears to play a role too, and on average, male 
users have a higher risk of dying of overdoses than their 
female counterparts. A recent review found that among opioid 
users, male overdose-related mortality was 1.7 times that for 
females (Degenhardt et al., 2011a). Explanations put forward 
for this include greater social isolation of male drug users 
(Darke et al., 2007a), and higher rates of alcohol use among 
male overdose cases (Bird and Robertson, 2011). 
The injection of illicit drugs carries the greatest risk of 
overdose, but all routes of administration can result in a fatal 
overdose. The majority of overdose deaths involve drug 
combinations, with alcohol and benzodiazepines being 
frequently associated in drug-induced deaths. The presence 
of diazepam was recorded in almost one-fifth (18%) of cases 
reported in 2006–07 in a study carried out in Scotland 
(Bird and Robertson, 2011). In Ireland, between 1998 and 
2007, benzodiazepines were implicated in nearly a third 
(31%) of all deaths by poisoning, with the annual number 
increasing from 65 in 1998 to 88 in 2007.
Each year, the presence of substances used in substitution 
treatment (methadone and buprenorphine) is reported in a 
number of overdose or poisoning deaths. Most are due to 
misuse or, in a small number of cases, to problems 
occurring during treatment. The role played by the 
substance is often unclear, as polydrug use is frequent and 
other drugs are often present. Factors involved in such 
deaths may include loss of opioid tolerance, excessive 
dosage or inappropriate use, such as irregular and 
non-therapeutic use. 
(8) See Figure DRD-3 in the 2011 statistical bulletin and EMCDDA (2010c).
A case vignette of an overdose death from the 
United Kingdom (1)
The average drug death victim from this area would be a white 
33-year-old man who had used drugs since he was 16. Around 
that time he would have left school and gained employment or 
started an apprenticeship. His childhood would have been 
disrupted, and he would have had a family history of 
psychiatric difficulties and/or substance misuse. He may have 
suffered physical or sexual abuse and possibly spent time in 
care. At first, he would have used a cocktail of drugs including 
cannabis, amphetamines, LSD and ecstasy, moving on to heroin 
about four years later. He would have started injecting at 
around 24 years of age. Throughout his life, he would have 
maintained meaningful and close relationships with his friends 
and family members, and would not have been socially 
isolated. He would have had children; however, they would not 
have lived with him. 
He would have been known to at least two services, 
intermittently, including his GP, criminal justice services and 
specialist substance misuse services during the five years prior 
to his death. In the six months before his death, he would have 
been arrested at least once. He would have committed crimes 
linked to his drug use, with charges such as possession of drugs 
or theft. At the time of his death, he would have been 
unemployed, living alone or with other adults and would not 
have changed accommodation type during those six months. 
He would have been classed as single, but may have been in 
an on/off relationship. He would have been known to his GP, 
but would not have sought or received pharmacological 
treatment for his drug dependency. During this time, he would 
be using a cocktail of illicit and prescribed substances. 
On the day of this death, he would have purchased at least 
one ‘tenner’ (2) bag of heroin alongside alcohol and 
benzodiazepines. He would have shared these among friends/
co-users and injected in their presence. He would have died in 
the presence of others who, believing him to be asleep would 
have been slow in attempting to revive him. Resuscitation would 
have only been conducted when instructed to do so by the 
ambulance, and would be partial in nature. He would have 
died at or near his resident home address, over a weekend, 
during the winter months. His blood sample would have 
revealed a cocktail of depressants such as morphine, 
benzodiazepines, alcohol and methadone. His cause of death 
would most likely have been classed as ‘adverse effects of 
heroin/morphine’.
(1)  This case vignette is a summary of an aggregate profile, derived from the characteristics of individual cases recorded in Fife (Scotland) between 
2008 and 2010, originally published in Neufeind et al. (2011). This ‘profile’ may not be representative of other drug user populations. It is 
presented to give an insight. Overdose victims are individuals and although there are common circumstances, each death is different. Context 
information is available from the report on Scotland’s National Drug Related Deaths Database published in January 2011 (Graham et al., 2011).
(2) GBP 10 (EUR 11.40). 
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Deaths due to buprenorphine poisoning are infrequently 
reported, despite the spread of its use in substitution 
treatment in most EU Member States (9). In France, where the 
majority of patients in opioid substitution treatment receive 
buprenorphine, the proportion of overdose deaths for which 
buprenorphine was recorded as the main substance involved 
was less than 10% in the latest year with available data 
(2008). In comparison, 36% of overdose deaths were 
attributed to ‘heroin alone or combined with other products’, 
and 29% to ‘methadone alone or combined with other 
products’ (10). Buprenorphine is a special case, though, for 
two reasons. First, because of forensic testing issues in some 
countries, as the substance might not be detected in post 
mortem analyses. And secondly, because buprenorphine is 
a partial agonist, which makes respiratory depression from 
buprenorphine overdose less likely than from other opioids 
such as heroin or methadone. Other synthetic opioids such 
as fentanyl have caused ‘outbreaks’ of overdoses in recent 
years, and these deaths should be closely monitored.
Finally, it is important to note that overdoses are likely to be 
underestimated. In some studies, up to half of drug user 
deaths can be classified as ‘other causes’, and some of these 
are likely to be overdose deaths. This is particularly likely in 
studies where high numbers of deaths are attributed to 
circulatory, or respiratory diseases, causes that should not 
be very common among young adults. Similarly, some 
causes such as death from ‘inhalation of vomit’ or ‘heart 
failure, unspecified’ could mask overdoses. 
Deaths caused by diseases
HIV and hepatitis C virus infection (HCV) are the two most 
common infectious diseases associated with illicit drug use, 
and injecting drug use in particular. In addition to overdoses 
and HIV/AIDS, a high proportion of deaths among drug 
users are accounted for by liver disease related to hepatitis C 
infection (HCV) and/or heavy alcohol use. In the future, with 
an ageing population of heroin users in Europe, it is likely 
that other diseases, particularly non-infectious diseases, will 
become more frequent causes of death among drug users.
HIV/AIDS
Following the widespread use of highly active antiretroviral 
treatment (HAART) in the mid-1990s, mortality rates among 
problem drug users reported in recent studies in Europe are 
much lower than those in the pre-HAART era. For example, 
in the EMCDDA COSMO group of studies, which enrolled 
opioid drug users in the early 1990s, HIV/AIDS caused 
more deaths than overdoses in both Barcelona and Lisbon. 
In Rome, the mortality rates for the two causes were about 
equal. At that time, the proportion of deaths among study 
participants due to HIV/AIDS reached 41% in Lisbon, 37% in 
Barcelona and 32% in Rome (Bargagli et al., 2006b). By 
contrast, recent studies generally show a lower proportion of 
deaths (usually less than 10%) due to HIV/AIDS in countries 
with low prevalence, although coding differences make 
comparison difficult (see Figure 3 and Table 1). 
A French cohort study among those arrested for drug law 
offences showed that the mortality rate from HIV/AIDS fell 
six-fold between the middle and the end of the 1990s 
(Lopez et al., 2004). 
Based on reported HIV/AIDS deaths and national AIDS 
surveillance data, it is estimated that there were around 
2 100 HIV/AIDS-related deaths in Europe attributable to 
injecting drug use in 2008. Overall, estimated population 
mortality rates due to HIV/AIDS attributable to drug injection 
are low, with the exception of Spain, Italy and in particular 
Portugal and the Baltic countries (Mathers et al., 2010). In 
most countries, drug-induced mortality is now considerably 
higher than the estimated HIV/AIDS-related mortality among 
drug users (11).
 (9) See Table HSR-1 in the 2011 statistical bulletin.
(10) Based on data from the regional forensic network DRAMES, which does not record all overdose cases in France.
(11) See Figure DRD-7 (part ii) in the 2011 statistical bulletin.
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A review of cohort studies found that all-cause mortality 
among HIV-positive drug users, mainly enrolled pre-HAART, 
was almost three times that among HIV-negative users, and 
that the elevated mortality rates were accounted for by 
AIDS-related deaths (Degenhardt et al., 2011a). Compared 
to those acquiring HIV infection by other routes (such as 
sexual transmission), lower survival rates are reported 
among those acquiring the infection through drug injecting 
(Lert and Kazatchkine, 2007; Rodriguez-Arenas et al., 
2006). For example in the Czech Republic, a statistically 
significant lower level of survival was found in those who 
contracted the infection through injecting drug use, 
compared to other transmission groups (Figure 4).
Hepatitis C
Hepatitis C virus (HCV) infection is highly prevalent among 
injecting drug users. The virus affects the liver and is spread 
primarily by exposure to human blood. In most developed 
countries, the predominant mode of HCV transmission is 
through injecting drug use, by shared use of injecting 
equipment. Surveillance data indicate that up to 63% of 
HCV cases in Europe are related to injecting drug use. 
Although the prevalence of HCV infection among injecting 
drug users varies considerably across Europe, of the 12 
countries with national estimates of HCV antibody levels 
among injectors for 2007/08, eight reported levels of over 
40%. High prevalence levels among young drug users and 
among recent injectors in certain countries suggest high 
rates of new infections (EMCDDA, 2011a). Many drug users 
are unaware of their infection, as illustrated by a study in 
Bristol that estimated that more than half of the injecting 
drug users who were HCV-positive were undiagnosed 
(Hickman et al., 2009). Once infected, very few clear the 
virus from their bodies. About three-quarters of all cases will 
go on to develop chronic infection and of these, around 7% 
will develop cirrhosis within 20 years of exposure to the 
virus. Of those with cirrhosis, each year 4% will experience 
liver failure and 2% will develop hepatocellular carcinoma. 
Thus, the high prevalence of HCV is likely to cause significant 
morbidity and mortality over time by liver cancer and 
end-stage liver diseases. Where the information is available, 
some cohort studies among problem drug users show that 
5% to 10% of the deaths could be due to viral hepatitis, but 
this is unclear as liver disease might be viral or due to 
alcohol, and the detailed information is not always available. 
A recent Scottish study in a cohort of young injecting drug 
users (median age 31 years) suggested that problematic 
alcohol use may have played a larger role in liver-related 
hospitalisations and mortality than HCV infection (McDonald 
et al., 2011). Infected problem opioid users can and do 
survive long enough to experience harms from this slowly 
developing liver condition. This may be seen in the findings 
of a study on an ageing cohort of problem opioid users in 
Australia, where deaths caused by viral hepatitis were twice 
as frequent as those attributed to alcoholic liver disease 
(Gibson et al., 2011). Overall, the Australian study reported 
a mortality rate due to liver diseases of 1.4 deaths per 
1 000 participants per year, 17 times higher than that 
among the general population.
The interaction between viral hepatitis and alcohol use must 
also be considered, as many drug users infected with HCV 
continue to use alcohol, as shown in a Spanish study of 497 
HCV-infected drug users admitted into treatment, which 
found that 32% reported daily alcohol consumption 
(Sanvisens et al., 2011).
Other infectious diseases that are far less prevalent than HIV 
or HCV but which have a high risk of death include, 
endocarditis, which can be contracted through the sharing 
of contaminated injecting equipment (Darke et al., 2007a). 
Anthrax is another infectious disease that caused deaths 
among injecting drug users recently in Europe. 
Contaminated heroin caused more than 50 confirmed 
anthrax cases and 17 deaths in an outbreak among heroin 
users in Scotland in 2009–10, and a small number of cases 
were also reported in Germany (Wiessing et al., 2010). 
Other diseases
Illicit drug use is also associated with a number of 
potentially fatal non-infectious diseases. Cardiovascular 
pathology is frequently reported as the cause of death 
among drug users, particularly older users. For example, a 
37-year follow-up study among illicit drug users in Sweden 
showed that 20% of opioid users and 14% of stimulant users 
died from cardiovascular diseases, mainly ischemic heart 
disease and cerebro-vascular diseases (Stenbacka et al., 
2010). There are some caveats though, as the coding of the 
causes of deaths are sometimes unspecific, and deaths 
attributed to cardiac causes might, in some cases, be due to 
overdose. Cardiovascular disease is also a consistent feature 
of heavy long-term use of psychostimulants, particularly 
cocaine and amphetamine (12). Non-infectious diseases that 
are commonly reported as the cause of death include lung 
diseases, such as pneumonia and chronic obstructive 
pulmonary diseases. Cancer accounts for a considerable 
(12) See the box ‘Mortality among cocaine and amphetamine users’.
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proportion of deaths, particularly among older drug users, 
as evidenced in long-term follow-up studies. For example the 
Australian study mentioned above reported that 14% of the 
deaths were due to cancer (Gibson et al., 2011), similar to 
the 13% (109/860) of deaths due to cancer reported in the 
37-year follow-up study in Sweden (Stenbacka et al., 2010). 
In the case of deaths due to somatic problems, there are 
often multiple underlying causes of death recorded. A 
Norwegian study of a cohort of opioid users described 213 
deaths, of which a third (32%) had a somatic cause. Three 
examples illustrate the very poor health among this cohort of 
drug users. Death was attributed to a combination of causes 
in the three cases: one to endocarditis, tuberculosis and 
hepatitis C; another to intracranial haemorrhage, hepatitis C 
and pneumonia; and a third to diabetes, stroke and kidney 
failure (Clausen et al., 2009). 
Suicide and trauma
Cohort studies carried out in some European countries indicate 
that deaths from suicide or trauma account for between 20% 
and 40% of mortality among problem drug users.
Suicide
Suicide presents a major clinical challenge for those treating 
problem drug users. Many recent cohort studies in Europe, 
for example in the Czech Republic, Germany, Italy, Sweden 
and Norway, report that suicide accounts for between 10% 
and 20% of deaths among problem drug users (Table 1, 
Appendix).
Depression is a key risk factor for suicide, and the prevalence 
of depressive disorders among problem drug users is high; 
for example 25% of entrants to treatment for heroin 
dependence in an Australian study reported current major 
depressive episodes (Teesson et al., 2005). The suicide rate 
among heroin users has been estimated to be 14 times that 
in the general population (Darke and Ross, 2002). The 
authors concluded that the major risk factors for suicide 
among the general population also apply to the heroin-using 
population (gender, psychopathology, family dysfunction and 
social isolation). Heroin users, however, have extremely wide 
exposure to these factors. Younger users also appear to be at 
greater risk, with teenagers and those in their 20s having the 
highest suicide rates (Oyefeso et al., 1999). In addition, the 
greater the number of childhood problems that illicit drug 
users have experienced, the greater the likelihood of 
attempted suicide (Rossow and Lauritzen, 2001).
Heroin users are more likely than the general population 
to use some type of drug when committing suicide, and 
Mortality among cocaine and amphetamine 
users 
In recent years, cocaine has been detected in an increasing 
number of drug-induced deaths reported in European 
countries. Although the available data do not permit a 
clear picture of cocaine trends in Europe as a whole, an 
increase was observed before 2008 in Spain and the 
United Kingdom, the two countries with the highest rates of 
cocaine use in the general population; but most recent data 
suggest the numbers have decreased since then. Cocaine is 
very rarely identified as the only substance contributing to a 
drug-induced death. 
A recent review on mortality among cocaine users 
(Degenhardt et al., 2011b) included nine studies in Brazil, 
Canada, the United States of America and three European 
countries (France, Italy, Netherlands). Crude mortality rates 
ranged from 0.54 to 4.6 per 100 person-years. The main 
causes of mortality, where known (Brazil, Canada, Italy, 
United States) included fatal gunshots (Brazil), overdose, 
HIV/AIDS and trauma and infections related to injecting, 
vascular diseases and suicide. The authors concluded that 
there are limited data available on the extent of elevated 
mortality among problematic or dependent cocaine users, 
and that it is unclear how generalisable the results may be 
to other populations. A recent Danish cohort study, 
however, among individuals in treatment for cocaine use, 
showed an excess mortality risk of 6.4 compared to same 
age and sex peers in the general population (Arendt et al., 
2011). Dependent cocaine users show high rates of 
attempted suicide. Suicide attempts are not restricted to 
injecting cocaine users; a study in Australia showed that 
10% of cocaine users who had never injected a drug also 
had this history (Darke and Kaye, 2004). 
A review of the literature on mortality cohort studies among 
problem amphetamines users found that crude mortality 
rates ranged from 0 in Australia to 2.95 per 100 person- 
years in Thailand (Singleton et al., 2009). Studies carried 
out in Europe found mortality rates ranging from 0.49 in 
Czech Republic to 2.89 in the Netherlands, with studies 
also reported in Sweden and Finland. The Czech cohort 
study reported an excess mortality risk compared to 
non-using peers of 6.2. Only three studies reported on 
causes of deaths (102 cases), and the majority were due to 
violence, injuries, accidents, and overdoses. There was 
suggestive evidence that injection of amphetamines was 
associated with higher mortality than other primary routes 
of administration. The authors concluded that given the 
widespread extent of problem amphetamine use, the known 
non-fatal adverse effects of use and the mortality rates 
reported, cohort studies investigating the morbidity and 
mortality associated with such drug use should be a 
research priority. 
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the substances most often implicated are medicines (in 
particular benzodiazepines and antidepressants). Heroin 
appears to play a relatively small role in suicide among 
this group, and most illicit drug user suicides employ 
means other than their drug of dependence (Darke et al., 
2007a).
A summary of studies carried out in Australia, Norway, the 
United Kingdom, Sweden and the USA found that between 
17% and 43% of problem drug users had attempted suicide, 
compared to 5% or under among community samples, and 
a previous suicide attempt is a strong predictor of 
subsequent attempts (Darke et al., 2007a, b). As in the 
general population, illicit drug users that complete suicide 
are predominantly males, whereas those who attempt 
suicide are predominantly females. 
Trauma
Trauma frequently accounts for at least 10% of deaths 
among drug users in Europe. Deaths caused by trauma 
mainly include those resulting from homicide, violence, 
accident and injury. Both contextual and psychological 
factors can explain why the rates of traumatic deaths are 
higher among illicit drug users than among the general 
population (Darke et al., 2007a). For those dependent on 
illicit drugs, the potential for violence is high, with many 
drug users turning to crime or sex work to support their drug 
use. An Australian study of 615 heroin-dependent users 
found that more than half of the men and a third of the 
women had been involved in at least one life-threatening 
accident, and two-thirds had been exposed to traumatic 
events including being threatened with a weapon, held 
captive or kidnapped. More than half of the women (54% of 
208) had been raped, a risk 10 times higher than in males 
(Mills et al., 2005). At the psychological level, a number of 
common psychiatric disorders, often associated with 
dependent drug use, are characterised by impulsivity, 
risk-taking and violent behaviour. 
Use of illicit drugs when driving is associated with increased 
risks of being involved in or causing an accident, and these 
risks increase when the drug is combined with alcohol or 
another substance (EMCDDA, 2008). In some studies, 
deaths due to road accidents represent a major component 
of overall trauma fatalities. Impairment due to intoxication 
may also increase the risk of fatal accidents such as falls 
from heights and drowning. A 37-year follow-up study 
among illicit drug users in Sweden showed that 15% of 
deaths (127/860 deaths) were due to accidents or homicide. 
The most common types were transport accidents, falls, and 
deaths resulting from ‘resisting the police’ (Stenbacka et al., 
2010). Around a fifth of the deaths in a Slovenian cohort 
were caused by trauma (including transport accidents, falls, 
assaults) (see Table 1), while 13% of the deaths in the 
Latvian cohort were due to trauma. In a Croatian study, 
traumatic deaths accounted for almost 10% of the total, and 
included various cranial, face, rest of the body injuries and 
wounds. Other studies, for example in Germany, Italy, 
Norway and Sweden describe ‘traumatic deaths’ as mainly 
relating to homicide, violence, accident and injury (13).
On average, drug users dying of trauma are often younger 
than those dying from chronic illnesses. This is illustrated by 
an analysis of drug-related deaths recorded in the Irish 
National Drug-Related Deaths Index (NDRDI) between 1998 
and 2007 (Lynn et al., 2009) (14). It is important to note that 
the study did not classify deaths according to intent and, as 
a result, a sizeable proportion of the deaths ascribed to 
trauma will have been suicides, as suggested by the many 
deaths due to hanging or drowning. The median age of 
those dying from trauma between 1998 and 2007 was 27 
years, and half of them (360) were aged between 20 and 
29 years. In contrast, the median age of drug users dying 
from medical causes was 39 years, and the majority of them 
were aged between 30 and 44 years (Lynn et al., 2009)
Women with drug problems are at particular risk of a 
trauma-related death, as illustrated by a study in Vancouver 
that followed 572 young (not older than 29 years) active 
injecting drug users (including 268 females) recruited 
through self-referral and street outreach. Of the 14 women 
dying during the study, nine were murdered, one died from 
an accident, one from an overdose and three from somatic 
causes (Miller et al., 2007). Most of the cohort participants 
lived in very difficult circumstances: 40% had a history of 
sex abuse, and in the six months prior to the study 25% 
were homeless and 44% did sex work. 
Risk factors for mortality
Mortality risk among drug users is heavily influenced by the 
drugs used and how they are consumed, with heroin being 
the drug most strongly associated with elevated mortality 
risk, and injecting the most risky form of administration. Risk 
of death is increased by older age, long-term use of drugs 
(13)  See the Appendix for details of the following studies: Clausen et al., 2009; Ferri et al., 2007; Fugelstad et al., 1997; Lejckova and Mravcik, 2005; 
Ødegård et al., 2007; Soyka et al., 2006; Stenbacka et al., 2010.
(14)  The NDRDI is an epidemiological database that records cases of death by drug and alcohol poisoning and deaths among drug users and alcohol 
dependents in Ireland.
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(in particular a long history of heroin use) polydrug use, 
somatic and psychiatric co-morbidity, and not being 
enrolled in drug treatment (Rome et al., 2008; Warner-Smith 
et al., 2001). 
Mortality risks vary depending on both circumstances and 
personal and social characteristics of drug users (15). Major 
factors identified include male gender, low education level, 
unemployment (Antolini et al., 2006), history of psychiatric 
admission, benzodiazepine prescription, length of drug 
career, use of antidepressants in the past month, 
psychopathology, particularly major depression, and 
post-traumatic stress disorder (Darke et al., 2007a; 
McCowan et al., 2009). A history of opioid overdose also 
increases the risk, as shown by the ATOS study in 
Australia, which followed 615 heroin users over the period 
2001–09. Drug users with a history of opioid overdose had 
a more than three times higher risk of death compared to 
those who had never overdosed. In addition to history of 
overdose, the ATOS study found that, independently of all 
other baseline characteristics, attempted suicide multiplied 
the risk by 1.4, being aged more than 30 years by 1.8 and 
use of benzodiazepine in the past month by 1.6 (Darke et 
al., 2011) 
Ageing drug users are particularly at risk, both for drug-
induced death and death from other causes. The available 
data on drug-induced deaths point to an ageing cohort of 
problem opioids users in many EU Member States (EMCDDA, 
2010c). In the most recent data, drug users aged 40 or more 
accounted for over a quarter of all reported drug-induced 
deaths, and the mean age of the cases is increasing in many 
countries. This is especially so for the pre-2004 EU Member 
States, which compared to those joining the EU since 2004, 
have longer-standing heroin problems. This might be 
explained by an increased vulnerability due to the cumulative 
toxicity of the drugs over the years, and by their poor health, 
with lung, renal and liver dysfunctions associated with 
ageing, and other chronic conditions such as cancer, liver 
cirrhosis and chronic bronchitis. A long-term cohort study in 
Stockholm illustrated the differences in mortality risk profile 
between younger and older users. It showed that 
cardiovascular disease and tumour were the most common 
causes of deaths in those aged more than 55 years, 
compared to accidents and suicide for those aged below 24 
years (Stenbacka et al., 2010).
In terms of contextual factors, the period following release 
from prison is a time of particularly high overdose risk for 
drug users, due to relapse into heroin use and reduced 
tolerance to opioids. A recent meta-analysis of studies in the 
United Kingdom, Australia and the United States of America 
found a three to eight-fold increased risk of drug-related 
death in the first one to two weeks after release compared 
with weeks 3 to 12. The study found that the risk remained 
elevated up to at least the fourth week (Merrall et al., 2010). 
In Ireland, an investigation of deaths among drug users 
following release from prison between 1998 and 2005 
showed a considerable risk of death at the time of release: 
out of 105 deaths observed after release from prison, 28% 
occurred within the first week of release with a further 18% 
in the first month. Opioids were implicated in 89% of all 
poisonings in the first month after release. Compared to 
other cases of drug-related deaths recorded in the national 
database in Ireland, former prisoners were very young (66% 
were aged between 20 and 29 years) and socially 
disadvantaged. They were more often unemployed (84%), in 
unstable accommodation, injectors and infected with HIV 
and hepatitis (Lyons et al., 2010). 
Although being in treatment, particularly in opioid 
substitution treatment, is a protective factor against mortality 
(Brugal et al., 2005; Clausen et al., 2008; Davoli et al., 
2007), there is a higher mortality risk linked to treatment 
drop-out and to relapse following drug-free treatment. In 
both of these cases, reduced tolerance to opioids can 
increase the risk of overdose mortality among drug users. 
With regard to medication-free inpatient treatment in 
Norway, a recent study suggests that the elevated risk of 
fatal overdose within the first four weeks of leaving is so 
dramatic that preventive measures should be taken (Ravndal 
and Amundsen, 2010).
(15) More information is available on health and social responses as well as on drug users in prison in the 2011 statistical bulletin.
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This Selected issue presents an overview of mortality related 
to problem drug use (mainly opioid use) in Europe and the 
main components of this mortality. This final section briefly 
summarises the key findings, provides an overview of the 
main responses to mortality related to drugs, and addresses 
the implications for future public health policy and practice 
in this area. 
Deaths related to drug use: a summary
During the last decade, many European countries have 
conducted cohort studies among problem drug users, mostly 
among those in treatment programmes, enrolled at the time 
of admission. Thousands of participants have been followed 
up, and their deaths recorded. These studies show extremely 
high rates of mortality among problem drug users 
(principally opioid users), with roughly 1% to 2% of study 
participants dying every year. Expressed another way, 
compared with their European peers of the same age and 
gender, problem drug users are 10 to 20 times more likely 
to die within a given time. Bearing in mind the data 
limitations and caveats (16), it can be roughly estimated that 
between 10 000 and 20 000 problem opioid users die 
every year in Europe. Eight in ten of these are male and 
most are heroin-dependent users. Based on cohort studies, 
the mean age of those dying is in the early to mid-thirties. 
These premature deaths result in hundreds of thousands of 
years of life lost at European level. Many of these deaths 
could be prevented. 
The majority of deaths among problem drug users can be 
attributed to so-called ‘external factors’ such as overdose, 
suicide and trauma. Deaths directly related to drug toxicity 
(overdose or drug-induced deaths) are a major cause of 
death for problem opioid and cocaine users, and typically 
account for between one-third to half of the deaths among 
problem drug users. There is a strong polydrug-use 
association here, with alcohol and benzodiazepines in 
particular. Drug-induced deaths are associated with certain 
high-risk situations such as lost tolerance to opioids after 
leaving prison or dropping out of treatment. In Europe, drug 
users older than 40 represent an increasing proportion of 
the 7 000 to 8 000 drug-induced deaths reported every 
year, particularly in the north of Europe and in the pre-2004 
EU Member States. 
After overdoses, disease is the second most important cause 
of death among problem drug users, particularly infectious 
diseases (HIV and hepatitis C), which are linked with 
sharing injection equipment. HIV/AIDS-related deaths 
among problem drug users declined substantially in Europe 
from a peak in the mid-1990s, but the estimated numbers 
and mortality rates are still high in some countries. It is 
estimated that in 2008, more than 2 000 HIV/AIDS deaths 
could be attributed to injecting drug use in Europe. In some 
cohort studies, up to one in five deaths among drug users 
are due to trauma and violence. Suicide also accounts for 
up to one in five deaths in some cohort studies. A 
considerable proportion of deaths among drug users 
remain poorly documented and understood (in particular 
suicide and trauma) and may be, to a large extent, more 
closely related to social exclusion, mental health problems 
and the life circumstances of problem drug users, than to 
drug use itself. 
Treatment is protective
Cohort studies show that stable retention in drug treatment 
programmes, particularly in opioid substitution treatment, is 
a protective factor against drug-related mortality (Brugal et 
al., 2005; Clausen et al., 2008; Davoli et al., 2007) (17). 
Long-term opioid substitution treatment has been shown to 
reduce rates of illicit drug use, drug injection and thereby 
mortality, in particular through reduction of overdose risks, 
infections and by improving physical health. A 20-year 
cohort study in New South Wales estimated that the 
state-wide opioid substitution programme produced a 29% 
reduction in mortality across the entire cohort (Degenhardt 
(16) See the box ‘How many Europeans die because of problem opioid use?’
(17) See the EMCDDA Best practice portal.
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et al., 2009). A Cochrane review comparing heroin-assisted 
treatment with methadone maintenance showed an even 
stronger reduction of mortality for this type of intervention 
(ECDC and EMCDDA, 2011).
An analysis of registered opioid substitution clients in 
Norway over seven years found a significant reduction 
between mortality risk prior to treatment, and mortality 
among those accepted in opioid substitution treatment. 
While in treatment, risk of overall mortality among clients 
was halved compared to the pre-treatment levels, and risk 
of mortality due to overdose was reduced to one fifth 
(Clausen et al., 2008). The need for continuity and for 
retaining patients in treatment is also highlighted by the 
Australian ATOS study, which examined a cohort of heroin 
users who had been through a range of treatments and 
were re-interviewed after 12 months (Darke et al., 2005). 
The study showed that the total number of treatment days 
received over the follow-up period was associated 
independently with a reduced risk of fatal and non-fatal 
overdose. In this group, each extra treatment day was 
associated with a 1% reduction in risk of overdose over the 
one-year period. By contrast, more treatment episodes were 
associated with an increased risk of overdose, which the 
authors concluded may arise from a pattern of treatment 
and relapse, with substantial variations in tolerance. Thus, 
for example, 100 days spent in one treatment episode 
would in all probability be more effective in reducing 
overdose than the same number of days accrued over five 
separate treatment episodes. 
There are, however, risks associated with treatment in 
some circumstances. For example, there is an increased 
mortality risk at the start of opioid substitution treatment, 
and immediately after stopping treatment (Cornish et al., 
2010). For this reason, treatment needs to be continuous 
and long-term to achieve the best protective effect. A study 
in the United Kingdom estimated that if the average 
duration of opioid substitution treatment approaches or 
exceeds 12 months, it has a greater than 85% chance of 
reducing overall mortality among opioid users (Cornish et 
al., 2010). 
Nevertheless, risk–benefit analysis shows clear advantages 
of appropriate provision of methadone maintenance 
treatment. With regard to methadone-related deaths in a 
population, a recent study in Scotland and England 
concluded that the introduction of supervised methadone 
dosing was followed by a substantial decline in deaths 
where methadone was involved. Between 1993 and 2008, 
there was at least a four-fold reduction in deaths due to 
methadone-related overdose per amount of methadone 
prescribed (Strang et al., 2010).
Overdose prevention
In addition to drug treatment, a number of other 
interventions can also reduce drug-related mortality 
(EMCDDA, 2010a). Overdoses are preventable and the risk 
factors are known (Darke et al., 2011). Preventive measures 
undertaken in many European countries include education of 
drug users on the risk of polydrug use (particularly co-use of 
benzodiazepines and alcohol with heroin), on recognising 
the signs of and managing overdose. With the aim of 
reducing overdose deaths, drug agencies in some countries 
provide take-home naloxone to heroin users, their peers and 
family. Facilities where health staff supervise drug 
consumption and intervene in emergencies also represent a 
key intervention for preventing overdose deaths at local level 
in some countries. Only a small proportion of overdoses 
result in death, and for each fatal overdose there may be up 
to 25 non-fatal ones (Darke et al., 2003; Warner-Smith et 
al., 2001). Many heroin users have overdosed more than 
once and overdose survivors are at elevated risk of dying of 
a subsequent overdose. 
History of overdose and risk of future overdoses need to be 
considered when assessing drug users entering treatment, 
and all clients would benefit from overdose prevention 
training (see above). Reduced levels of opioid tolerance 
significantly increase risk of overdose and death for drug 
users leaving prison (Farrell and Marsden, 2008), and the 
World Health Organisation recommends a close linkage of 
prison health with community drug services in order to 
ensure continuity of care (WHO Regional Office for 
Europe, 2010). 
Prevention and control of infectious 
diseases 
Since the emergence of the HIV epidemic among injecting 
drug users in the mid-1980s, many European countries 
have implemented evidence-based measures to prevent 
and control infectious diseases among this group. In the 
1990s, EU Member States started to develop common 
prevention policies in the field of HIV, and in the past two 
decades, prevention and treatment interventions have 
expanded significantly. According to reports from 2009, 
many countries have established needle and syringe 
programmes with adequate coverage among injecting 
drug users, and more than half of the estimated population 
of problem opioid users in the European Union received 
substitution treatment. 
Deaths from infectious disease can occur a long time after 
initiation of drug use, and the prognosis is influenced by a 
range of factors, among them access to the appropriate 
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treatment. The roll-out of antiretroviral treatment had a 
major impact on HIV/AIDS mortality among drug users. 
Mortality from hepatitis C virus (HCV) infection attributable 
to injecting drug use is likely to represent a major burden 
for public health in the future, with deaths occurring 
typically 20 or 30 years after infection. Alcohol co-
dependence worsens the prognosis for HCV infection, and 
also needs to be addressed by treatment services. It has 
been shown that a pragmatic public health prevention 
approach can have a strong effect on reducing the spread 
of blood-borne and other infections among injecting drug 
users. Prevention is feasible and effective, if properly 
implemented. Joint guidance by ECDC and EMCDDA 
(2011) recommends a set of evidence-based key 
intervention components (18).
Prevention of suicide and trauma-related 
deaths 
Suicide and trauma are among the causes of death for 
problem drug users that have received less attention, despite 
indications that they have a considerable public health 
impact. In contrast to overdose deaths, suicide and trauma 
are not specific to the drug-using population, but they are 
more frequent among drug users. This relates in part to the 
characteristics and difficulties experienced by problem drug 
users (depression, marginalisation and violence), and points 
to the need for comprehensive interventions, beyond drug 
treatment.
Suicidal intent is a major clinical problem among drug users 
in treatment and represents a substantial challenge for drug 
services; it is a problem that needs to be addressed in 
addition to the treatment of drug dependence. On treatment 
entry, drug users should be assessed for risk factors for 
suicide, such as depression, prior suicide attempts, 
psychiatric co-morbidity, family and social difficulties and 
dysfunction, and appropriate psychological and/or 
pharmacological treatment provided (Darke et al., 2007a). 
Deaths among drug users due to trauma are poorly 
documented, and although they represent a considerable 
proportion of mortality among drug users, their full extent is 
not known. Understanding the role and risk factors for 
trauma, which accounts in some studies for up to one in five 
deaths, represents a significant research priority. 
(18) See the box ‘Key intervention components to reduce infections in people who inject drugs’.
Key intervention components to reduce 
infections in people who inject drugs 
Injection equipment. Provision of, and legal access to, clean 
drug injection equipment, including sterile needles and 
syringes, free of charge, as part of multi-component 
prevention, harm-reduction, counselling and treatment 
programmes.
Vaccination. Hepatitis A and B, tetanus, influenza vaccines, 
and, in particular for HIV-positive individuals, 
pneumococcal vaccine.
Drug dependence treatment. Opioid substitution treatment 
and other effective forms of drug treatment. 
Testing. Voluntary diagnostic testing with informed consent 
for HIV, HCV (HBV for unvaccinated persons) and 
tuberculosis (TB) should be routinely offered and linked to 
referral to treatment.
Infectious disease treatment. Antiviral treatment based on 
clinical indications for those who are HIV, HBV or HCV-
infected. Anti-tuberculosis treatment for active TB cases. TB 
prophylactic therapy should be considered for latent TB cases.
Health promotion. Health promotion focused on safer 
injecting behaviour; sexual health, including condom use; 
disease prevention, testing and treatment.
Targeted delivery of services. Services should be combined 
and organised and delivered according to user needs and 
local conditions; this includes the provision of services 
through fixed sites offering drug treatment, harm reduction, 
counselling and testing, and referrals to general primary 
health and specialist medical services.
Source: ECDC and EMCDDA (2011).
23
Improving our understanding of trends
Recent years have seen a substantial increase in the number 
of problem drug users accessing treatment in Europe, 
accompanied by a notable reduction in levels of injecting 
drug use. In addition, the evidence shows a major reduction 
in drug user deaths from HIV/AIDS since the introduction of 
HAART in the mid-1990s. Yet, in spite of these encouraging 
trends, the overall mortality rates among problem drug users 
in cohort studies have remained relatively stable, at 1% to 
2% a year, and the numbers of drug-induced deaths have 
either remained stable or slightly increased in most reporting 
countries since 2003. This is a complex and surprising 
situation which needs further investigation and explanation.
Several factors identified in this Selected issue begin to help 
explain why total numbers of drug-related deaths and 
mortality rates have not decreased overall in Europe despite 
increases in protective factors. First, the population of 
problem drug users is ageing, as shown by the increased 
average age of reported overdose deaths in many countries. 
The cumulative effects of harmful lifestyles, including 
smoking, heavy alcohol consumption and injecting drugs, 
cause complex somatic problems. Older drug users are more 
at risk of dying of chronic conditions such as cancer, 
cardiovascular and neurovascular diseases, and moreover, it 
is estimated that the ageing process among older dependent 
drug users is accelerated by at least 15 years. At the age of 
40, drug users may need a level of care corresponding to 
that required by non-substance using elderly people 
(EMCDDA, 2010c). In addition, a high proportion of liver 
diseases associated with long-term exposure to alcohol, as 
well as hepatitis, are more commonly reported in these 
ageing populations. These are key elements in the apparent 
increase in the proportion of deaths listed under ‘other 
causes’. Secondly, deaths from suicide, violence and trauma 
continue to represent a sizeable proportion of all drug-
related deaths. Finally, while drug treatment has an overall 
protective effect against mortality, some deaths continue to 
be linked to substitution drugs. This can include overdoses on 
substitution drugs obtained from illicit markets, as well as 
overdoses linked to both the start of opioid substitution 
treatment and stopping treatment.
From the studies analysed here, it has not been possible to 
identify clear geographical patterns or regional trends 
within Europe with regard to mortality rates and causes of 
deaths among drug users. This could be further investigated, 
in particular through comparable prospective studies among 
drug users enrolled in drug treatment. A better 
understanding of drug-related mortality in each country (or 
group of countries) is needed in order to ensure that 
interventions and policies are appropriate and targeted on 
those in need. 
Improving information from cohort 
studies
Increased coordination and comparability between the 
many cohort studies that are underway in European 
countries could deliver deeper insights and be of 
considerable value, both at the national and European level. 
Improved cooperation and collaboration between treatment 
services and researchers conducting mortality studies may 
lead to a better understanding of the phenomenon.
Completing the picture of drug-related mortality in Europe 
will also require the implementation of cohort studies in those 
Member States that have not yet done so. The insights such 
studies offer into mortality among problem drug users and 
into the effectiveness of interventions require relatively little 
investment. There is no need to set up expensive multisite 
prospective studies, with extensive questionnaires and 
follow-up interviews. At the simplest level, all that is required 
is linkage of data between treatment centres and mortality 
registries, which can be achieved by cooperation between 
the institutions responsible of the respective databases — 
within the scope allowed by national regulations on personal 
data protection. The EMCDDA helps in this task by promoting 
standard methodology and offering technical assistance and 
by disseminating the findings of studies. 
There are considerable difficulties in attributing accurate 
cause of death in many cohort studies. Large ‘unknown’ 
categories are evident in some studies, and there are 
limitations in accessing the data on the causes of deaths in 
some countries. For example in Poland, for data protection 
Towards a better understanding of drug-related mortality  
for more effective action
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reasons, as well as in Austria, where only the deaths related 
to overdoses could be documented in a recent cohort study. 
Limited work has been carried out in Europe on the 
aetiological fractions of deaths caused by illicit drug use 
(e.g. the proportion of all deaths due to suicide in the 
population that can be attributed to problem drug use). 
Where studies have been carried out into the role of drugs 
in mortality among the population (e.g. Germany, 
Netherlands), the focus has been on the licit substances 
alcohol and tobacco. One cause of death for which the 
illicit-drug attributable fraction has been estimated for 
European countries is HIV/AIDS mortality (19), but other 
causes need to be included, and cohort studies can play an 
important part in this work. 
Most cohort studies focus on treatment populations, and it is 
difficult to transfer their results to other more ‘hard to reach’ 
populations of drug users (e.g. those not in contact with drug 
treatment). These drug users should be a priority for new 
studies, as they are likely to be even more disadvantaged, 
and to warrant priority interventions. Similarly, there is 
limited information about mortality of problem or intensive 
users of drugs other than opioids (20). 
Conclusion
Use of opioids, in particular heroin, continues to account for 
the majority of deaths related to illicit drug use in Europe. 
But as patterns of drug use continue to change, new studies 
are needed to monitor the effects of these changes on the 
public health impact of drug use. Cardiotoxicity of cocaine 
and, to a lesser extent, amphetamine warrants attention, as 
some countries report increasing levels of use. Similarly, 
synthetic opioids such as fentanyl have caused ‘outbreaks’ of 
overdoses in recent years, pointing to the need to closely 
monitor changes in patterns of drug use that may be 
associated with elevated risks of mortality.
Overall, Europe’s population of problem drug users is 
ageing, and some countries are now reporting that over a 
third of overdose deaths are aged 40 or more. In addition to 
the risk of overdose death, the detrimental and cumulative 
effects of long-term drug use on the physical, mental and 
psychosocial health of these users places them at high risk of 
mortality due to other causes. The challenge for European 
countries is to provide for the special needs of this older 
population — success in this area will be reflected in 
improvements in the quality and length of life for this 
high-risk group. 
(19) See Table DRD-5 (part iii) in the 2011 statistical bulletin.
(20) See the box ‘Mortality among cocaine and amphetamine users’.
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Appendix: Selected mortality studies among problem drug users in 
Europe, published since 1995 or reported to the EMCDDA
Table A1: Selected mortality studies among problem drug users in Europe, published from 1995 or reported to 
the EMCDDA
Country  
(study) 
reference
Timescale 
(enrolment) 
end of follow-up
Design 
(recruitment setting) 
Inclusion criteria Number 
of deaths 
reported
Person-years 
followed up 
(number of 
participants)
All-cause 
mortality rates 
per 1 000 
person-years 
(95 % CI)
Excess risk 
(SMR) (1)
8 EU countries 
(COSMO group 
with EMCDDA), 
Bargagli, 
2006b
1990–98 Drug treatment 
centres
Opioid users 3 221 159 030 From 10 
(London, 
Dublin) to 20 
(Roma) and 38 
(Barcelona)
—
Bulgaria, 
unpublished *
(1999) 2008 Outpatient and 
inpatient treatment 
centres
Opioid users 71 6 011 (652; 
532 males)
11.8 —
Czech Republic, 
Lejckova and 
Mravcik, 2005
1997–2002 and 
2000–02
Hospitalised for 
drug-related 
behavioural disorders 
(a, n = 12 207; b, n = 
2 824); injecting drug 
users with viral 
hepatitis (c, n = 
1 998); substitution 
clients (d, n = 706)
Identified as drug 
users in three 
health registers; 
aged 15–49 at 
treatment intake
476 38 131 
(18 772)
a 8.4 
b 15.4 
c 7.2 
d 7.2 
8 to 11
Czech 
Republic *
1997–2007 Problem drug users 
aged 15–39 
Hospitalised in 
1997–2007 with 
diagnosis of drug 
use-related 
disorders; patients 
in substitution 
treatment in 
2000–07
1 045 72 741 
(27 475)
6.5 4 to 11
Czech Republic, 
Zábransky et 
al., 2011
(1996–98) 
2008
2 low-threshold 
centres; 1 inpatient 
centre; 1 juvenile 
correctional 
institution; 1 juvenile 
institution for 
vulnerable youngsters
Opioid users, 
methamphetamine 
users, other drug 
users
8 1 660 (185) 4.8 overall 
7.2 for opioid 
users
9 (5–19) 
14 (6–34) for 
opioid users
Germany 
(PREMOS-
COBRA), 
Soyka et al., 
2011
(2003–06)  
2007
Patients from 
representative 
treatment facilities
Substitution 
treatment
131 (1 624) 11.5 —
Germany 
(COBRA), 
Soyka et al., 
2006
Opioid dependent 
patients. Baseline and 
1-year prospective 
follow-up data of the 
COBRA study
223 substitution 
physicians
28 (2 694) 10.4/1 000 
persons
—
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Country  
(study) 
reference
Timescale 
(enrolment) 
end of follow-up
Design 
(recruitment setting) 
Inclusion criteria Number 
of deaths 
reported
Person-years 
followed up 
(number of 
participants)
All-cause 
mortality rates 
per 1 000 
person-years 
(95 % CI)
Excess risk 
(SMR) (1)
Ireland (ROSIE), 
Comiskey et al., 
2008
(2003–04)  
2007
Inpatient facilities or 
outpatient settings
Opioid users, over 
18 years, entering 
treatment
6 (404) 5/1 000 
persons
—
France, 
Lopez et al., 
2004
(1992)  
2001
Data linkage (arrest 
data and national 
mortality data)
Arrested for 
offences related to 
heroin or crack 
cocaine
1 016 (~23 000) 
82 % males
All 7.3 
Females 5.3 
Males 7.7
—
France, 
Marzo et al., 
2008
(2003)  
2006
50 prisons Opioid 
dependents newly 
incarcerated
10 (500) 1 % per year —
Italy (VEdeTTE), 
Ferri et al., 
2007
(1998–2000) 
2001
Public treatment Heroin users 190 (1 376) 
86 % males
All 12 
Males 12.7 
Females 8.4
Females 22.8 
(16.5–31.5) 
Males 6.7  
(5.7–7.8)
Latvia  
(multiple 
cohorts), 
unpublished *
(1999–2006) 11–44 years 279 19 566 
(5 323)  
79 % males
All 11.3 
Females 8.7 
Males 12.0
All 7.5  
(6.65–8.43) 
Females 
13.24 
(9.66–17.72) 
Males 5.07 
(4.44–5.76)
Latvia  
(treatment 
study), 
unpublished *
(2000–09) 
2009
Outpatient treatment, 
public treatment
Opioid users, 
enrolled at date of 
first treatment
341 21 294 
(3 644)  
80 % males
21.6 All 9  
(8 to 10) 
Males 6  
(5 to 7) 
Females 19 
(14 to 24)
Latvia, Riga  
(arrestees 
study), 
unpublished *
(2000–09) 
2009
Drug testing facility Subjects tested 
positive for opioid 
use, arrestees
416 24 873 
(4 825)  
81 % males
20.3 All 8.5  
(7.7 to 9.4) 
Males 5.8  
(5.2 to 6.4) 
Females 14.2 
(10.7 to 18.4)
Lithuania, 
unpublished *
2001–07 Inpatient and 
outpatient drug 
treatment centres
All registered 
clients who 
applied for 
drug-related 
treatment
316 ~4000
Netherlands, 
Amsterdam, 
unpublished *
(1985–2009) 
2009 
Outpatient methadone 
treatment. Open 
cohort. No a priori 
fixed period of 
follow-up
Methadone 
patients living in 
Amsterdam who 
were born in the 
Netherlands, 
Surinam, the 
Netherlands  
Antilles, Morocco, 
or Turkey
94 4.3 4.5
Austria, 
unpublished *
(2000–08) 
2008
Substitution treatment 
register linked to 
special mortality 
register. Only 
overdose deaths are 
available
Polydrug users 
including opioids
200, only 
overdoses
35 435 
(9 716) 
74 % males
Overdose 
mortality rate: 
All 5.6 
Males 6.4 
Females 3.5
—
Poland, 
unpublished *
(2000–04) 
2006
Residential psychiatric 
drug treatment
1 744 96 038 
(22 984)  
75 % males
18.2 All 6.5  
(6.2 to 6.8) 
Males 7.5  
(7.1 to 7.9)  
Females 4.6 
(4.1 to 5.0)
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Country  
(study) 
reference
Timescale 
(enrolment) 
end of follow-up
Design 
(recruitment setting) 
Inclusion criteria Number 
of deaths 
reported
Person-years 
followed up 
(number of 
participants)
All-cause 
mortality rates 
per 1 000 
person-years 
(95 % CI)
Excess risk 
(SMR) (1)
Romania, 
unpublished *
(2001–06)  
2010
In- and outpatient 
treatment centres
Opioid users 116 20 188 
(2 707)  
835 males
All 9.2 
Males 7.1 
Females 11.3
All 6.5  
(5.4 to 7.7) 
Males 6.3  
(5.2 to 7.6) 
Females 8.7 
(4.8 to 15.7)
Slovenia, 
unpublished *
(2004–06) 
2006
Outpatient treatment 
centres
Clients first 
entering the 
treatment centre 
from 2004
69 8 548 
(3 950) 76 % 
males, 
including 
3 423 opioid 
users (87 %)
All 8 
Males 8.3 
Females 5
All 9  
(7.1 to 11.4) 
Males 9.2  
(7.2 to 11.8) 
Females 6.6 
(2.7 to 15.8)
Sweden, 
Stockholm  
region, 
unpublished *
(1981–88) 
2007
Inpatient treatment Illicit opioid users 343 10 307 (678) All 19 
Males 23  
Females 14
All 27.6  
(24.9 to 
30.7) 
Males 24.7 
(21.8 to 27.8) 
Females 28.9 
(23.2 to 
35.2)
Sweden, 
Stockholm 
region, 
unpublished *
(1981–88) 
2007
Inpatient treatment Illicit amphetamine 
users
153 10 904 All 7 
Males 7 
Females 6
All 9.1  
(7.7 to 10.6) 
Males 7.7  
(6.3 to 9.2) 
Females 11.1 
(8 to 15.1)
Sweden, 
Stockholm 
region *
(1981–88) 
2007
Inpatient treatment Illicit drug users 
HIV-positive at 
entrance
171 2 882 All 30  
Males 30 
Females 30
All 53  
(46 to 52) 
Males 46  
(38 to 54) 
Females 62.4 
(47.2 to 80.9)
United Kingdom, 
(National 
Treatment 
Outcome 
Research Study), 
Gossop et al., 
2002
(1995) 
2000
Drug treatment 
patients 
After five 
years: 62
(1 075) 12 PY survival: 
1 year,:1.5 % 
died; 4 years: 
5 % died; 5 
years: 6 % died
—
United Kingdom, 
Scotland 
(Drug Outcome 
Research in 
Scotland), Bloor 
et al., 2008; 
McKegany et 
al., 2008
(2001–02) 
2004–05
Treatment settings, 
prospective study of 
treatment 
effectiveness
15–54 years 
problem drug 
users starting a 
new treatment 
episode in 
2001–02 (9/10 
had used heroin in 
the past 3 months)
38 (1 033) 13.5  
(95 % CI 
10–18) 
Overdose 
mortality rate 8 
(95 % CI 5–12) 
12
United Kingdom, 
England, 
Hickman et al., 
2003
(1997 to 2001) Heroin users 33 (881) 1.61 per 100 
person year
Females 17.7 
Males 16.8
United Kingdom, 
Scotland, 
McCowan et al., 
2009
(1993–2004) 
1993–2004
Methadone 
patients
181 (after 
12 years)
(2 378) — —
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Country  
(study) 
reference
Timescale 
(enrolment) 
end of follow-up
Design 
(recruitment setting) 
Inclusion criteria Number 
of deaths 
reported
Person-years 
followed up 
(number of 
participants)
All-cause 
mortality rates 
per 1 000 
person-years 
(95 % CI)
Excess risk 
(SMR) (1)
United Kingdom, 
Scotland 
(Edinburgh), 
Kimber et al., 
2010; Macleod 
et al., 2010
(1980–2007) 
2006
Primary healthcare 
setting
Opioid users 
prescribed and 
dispensed liquid 
methadone
228 10 390 (794) 
68 % males
21.9 —
Croatia 
(Zagreb) *
(2000–06) 
2007
In- and outpatient 
treatment centres
Opioid injectors 174 15 968 
(3 059)  
78 % males
All 10.9 
Males 12.6  
Females 4.9
All 10.3  
(8.9 to 12) 
Males 10.4 
(8.9 to 12.2) 
Females 9.9 
(6.1 to 16.1)
Norway * (1972–76) 
1999
Infection medicine unit Drug users 
enrolled in the unit
68 5 418 (214) 
61 % males
— —
Norway * (1981–91) 
2003
National Clinic for 
Drug Abusers 
(inpatient)
All drug users who 
received treatment
189 (501)  
61 % males
23.4 —
Norway * (1998–99) 
2006
11 inpatient 
institutions 
Problem drug 
users
36 (300)  
70 % males
— 21
Norway * (1998–2003) 
2007
Outpatient treatment 
(short period inpatient 
included)
Opioid users 213 10 934 
(3 789) 
68 % males
* Data reported to the EMCDDA by the national experts.  
(1) SMR, standardised mortality ratio.
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Cohort study: a type of longitudinal study that follows a 
group of people (cohort) over time, with the purpose of 
analysing risk factors and identifying events that occur to 
these people (e.g. illness, death). Cohort members may be 
tracked by re-contacting them or by record linkage, which 
involves checking their status in other databases (e.g. 
mortality registry). 
Crude mortality rate: a measure of the number of 
deaths (in general or due to a specific cause) in a 
population, scaled to the size of that population, per unit 
time. It is typically expressed as either deaths per 100 or 
1 000 individuals per year.
Drug-induced deaths: defined by the EMCDDA as those 
of ‘people who die directly due to use of illegal substances, 
although these often occur in combination with other 
substances such as alcohol or psychoactive medicines. 
These deaths generally occur shortly after the consumption 
of the substance.’ These deaths are also known as overdoses 
or poisonings.
Drug attributable fraction: the fraction of deaths 
(overall or due to specific causes) in a population to which 
drug use is the main or a contributing cause (e.g. the 
proportion of HIV/AIDS deaths that is attributable to 
injecting drug use).
Problem drug use: the EMCDDA operationally defines 
problem drug use as ‘injecting drug use or long-duration/
regular use of opioids, cocaine and/or amphetamines’. Most 
cohort studies on drug users are conducted among problem 
drug users, and in particular among problem opioid users. 
Standardised mortality rate: a crude mortality rate 
that has been adjusted for differences in age composition 
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